Biogen Inc (NASDAQ:BIIB) stock originally popped after rumours hit the mill that a buyout was in the making. Even though the news that followed trumped that idea as Allergan, Inc. denied those rumours, BIIB stock still …
The share price of Biogen Inc. (NASDAQ:BIIB) tumbled as much as 8 percent, to $395, Friday after sales of …
Another company in this space everyone’s watching is Biogen (BIIB). If I …
Alzheimer's disease
Equities research analysts at Cantor Fitzgerald issued their FY2017 earnings per share (EPS) estimates for Biogen in a report issued on Wednesday. Biogen Inc. has a consensus outperform rating from 27 Wall Street …
Today's Most Active Call & Put Options of the S&P 500 » Biogen Inc (BIIB) options are showing a volume of 10,399 contracts thus far today. That number of contracts represents approximately 1.0 million underlying …
As for BIIB, the stock is nearing the 320-day moving average, a trendline that has historically resulted in outsized gains, looking back over the last three years. Specifically, the shares have moved higher three of the past four …
With its market value over its outstanding shares, Biogen Inc. (NASDAQ:BIIB) Biotechnology has a market capitalization valued at Biotechnology. As the outstanding stock of Biogen Inc. NASDAQ:BIIB Biotechnology …
NASDAQ
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here. Leerink Partners analyst, Geoffrey …
In reaction to the CTAD abstracts that have investors excited, the analyst reiterates an Overweight rating on …
Divided
The biotech's stock price has shot up more than 60% year to date and at ... AVXS-101 is the first gene therapy to be studied for the indication. Biogen (NASDAQ:BIIB) won approval for its SMA drug, Spinraza, in December. …
The Motley Fool